Two cases of burning mouth syndrome treated with olanzapine
Article first published online: 28 JUN 2008
© 2008 The Authors. Journal compilation © 2008 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 62, Issue 3, pages 359–361, June 2008
How to Cite
Ueda, N., Kodama, Y., Hori, H., Umene, W., Sugita, A., Nakano, H., Yoshimura, R. and Nakamura, J. (2008), Two cases of burning mouth syndrome treated with olanzapine. Psychiatry and Clinical Neurosciences, 62: 359–361. doi: 10.1111/j.1440-1819.2008.01806.x
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Received 4 October 2007; revised 22 November 2007; accepted 21 December 2007.
- burning mouth syndrome;
- oral symptoms;
- somatoform disorders
Two case reports of patients suffering from burning mouth syndrome (BMS), a type of somatoform disorder, who were treated with olanzapine are discussed. One case was a 54-year-old female with BMS who failed to respond to milnacipran treatment. Olanzapine (2.5 mg/day) brought about dramatic improvement in the patient's symptoms, and thereafter milnacipran withdrawal further eliminated her symptoms. The second case was a 51-year-old male with BMS who failed to respond to paroxetine treatment. Olanzapine (2.5 mg/day) was added to the treatment regimen and increased to 5.0 mg/day the following week. The patient noted a reduction in symptoms and continued to live normally thereafter without experiencing severe symptoms. These findings suggest that olanzapine may be useful in the treatment of BMS.